Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: J Allergy Clin Immunol. 2018 May 2;142(1):335–338.e9. doi: 10.1016/j.jaci.2018.04.016

TABLE E2.

Baseline characteristics of children and upstream predictors of the intestinal microenvironment

All subjects (n = 83)
Subjects with iNKT-cell activity data (n = 57)
Characteristic All children (n = 81) Food allergic (n = 12) Food sensitive (n = 32) Control (n = 37) P value Food allergic (n = 8) Food sensitive (n = 22) Control (n = 27) P value
Sex, n (%) .66 .17
 Male 41 (51) 5 (42) 18 (56) 18 (49) 2 (25) 14 (64) 13 (48)
 Female 40 (49) 7 (58) 14 (44) 19 (51) 6 (75) 8 (36) 14 (52)
Race/ethnicity, n (%) .94 .98
 Black, non-Hispanic 34 (42) 6 (50) 13 (41) 15 (41) 4 (50) 9 (41) 10 (37)
 White, non-Hispanic 26 (32) 4 (33) 11 (34) 11 (30) 2 (25) 6 (27) 9 (33)
 Hispanic 21 (26) 2 (17) 8 (25) 11 (30) 2 (25) 7 (32) 8 (30)
Birth by Cesarean section, n (%) 24 (30) 6 (50) 5 (16) 13 (35) .052 5 (63) 2 (9) 9 (33) .01
Gestational age (wk), mean ± SD 39.1 ± 1.6 39.4 ± 1.7 38.9 ± 1.9 39.4 ± 1.4 .48 39.3 ± 1.6 38.8 ± 2.2 39.4 ± 1.4 .79
Number of living children born to mother, mean ± SD 0.9 ± 0.9 1.2 ± 0.9 1.0 ± 0.9 0.8 ± 0.9 .40.16 1.3 ± 0.9 0.8 ± 0.8 0.8 ± 0.9 .36
Antibiotic exposure, n (%)
 Perinatal antibiotics 35 (43) 8 (67) 11 (34) 16 (43) .16 5 (63) 8 (36) 11 (41) .44
 By age 6 mo 15 (19) 2 (17) 5 (16) 8 (22) .86 1 (13) 3 (14) 7 (26) .59
 By age 3 y 69 (85) 11 (92) 29 (91) 29 (78) .36 7 (87) 21 (95) 20 (74) .10
Pet dog in home, n (%)
 In first 6 mo of life 22 (28) 3 (33) 6 (19) 13 (36) .31 2 (25) 3 (14) 10 (37) .19
 Between age 6 and 36 mo 32 (41) 3 (33) 13 (43) 16 (43) .52 2 (25) 10 (50) 11 (41) .53
Pet cat in home, n (%)
 In first 6 mo of life 11 (14) 2 (17) 4 (13) 5 (14) .91 1 (13) 2 (9) 4 (15) .86
 Between age 6 and 36 mo 20 (25) 6 (50) 5 (17) 9 (24) .10 3 (38) 2 (10) 6 (22) .22
Daycare by age 3 y, n (%) 43 (53) 7 (58) 15 (47) 21 (57) .72 4 (50) 10 (45) 14 (52) .93
Age at stool sample collection (mo), mean ± SD 4.6 ± 1.1 5.0 ± 1.0 5.0 ± 1.0 4.1 ± 1.0 <.01 5.0 ± 1.0 5.1 ± 1.0 4.2 ± 1.1 .02
Diet at stool sample collection, n (%)
 Breast-feeding 34 (42) 6 (50) 13 (41) 15 (41) .91 4 (50) 7 (32) 12 (44) .57
 Formula 50 (62) 7 (58) 20 (63) 23 (62) 1 4 (50) 16 (73) 17 (63) .51
 Solid foods 33 (41) 6 (50) 19 (61) 8 (22) <.01 4 (50) 12 (57) 7 (26) .07
Asthma/recurrent wheeze by age 3 y, n (%) 25 (31) 8 (67) 9 (28) 8 (22) .02 6 (75) 7 (32) 4 (15) <.01
VDAART treatment group, n (%) 1 1
 4400 IU/d vitamin D 41 (51) 6 (50) 16 (50) 19 (51) 4 (50) 11 (50) 13 (48)
 400 IU/d vitamin D 40 (49) 6 (50) 16 (50) 18 (49) 4 (50) 11 (50) 14 (52)
Study center, n (%) .27 .71
 Boston 23 (28) 4 (33) 8 (25) 11 (30) 1 (13) 2 (9) 7 (26)
 St Louis 42 (52) 7 (58) 20 (63) 15 (41) 3 (38) 7 (32) 9 (33)
 San Diego 16 (20) 1 (8) 4 (13) 11 (30) 4 (50) 13 (59) 11 (41)
Maternal education, n (%) .92 .74
 Less than high school 10 (12) 1 (8) 3 (9) 6 (16) 0 (0) 3 (14) 4 (15)
 High school or technical school 26 (32) 5 (42) 11 (34) 10 (27) 4 (50) 8 (36) 6 (22)
 Some college 10 (12) 2 (17) 4 (13) 4 (11) 1 (13) 3 (14) 3 (11)
 College graduate or graduate school 35 (43) 4 (33) 14 (44) 17 (46) 3 (38) 8 (36) 14 (52)
Household income (US $), n (%) .57 .55
 <30,000 29 (36) 6 (50) 12 (38) 11 (30) 5 (63) 8 (36) 8 (30)
 30,000–49,999 11 (14) 1 (8) 5 (16) 5 (14) 0 (0) 4 (18) 4 (15)
 50,000–74,999 9 (11) 1 (8) 3 (9) 5 (14) 1 (13) 3 (14) 4 (15)
 75,000–99,999 8 (10) 1 (8) 1 (3) 6 (16) 1 (13) 0 (0) 4 (15)
 100,000–149,999 10 (12) 2 (17) 2 (6) 6 (16) 1 (13) 1 (5) 4 (15)
 At least 150,000 5 (6) 0 (0) 4 (13) 1 (3) 0 (0) 2 (9) 1 (4)
 Refused to say or unknown 9 (11) 1 (8) 5 (16) 3 (8) 0 (0) 4 (18) 2 (7)

P value is for Kruskal-Wallis test for comparisons of gestational age, birth order, and age at stool sample collection. P value is for Fisher exact test for all other comparisons. Missing data: breast-feeding status for 1 subject, solid foods status for 1 subject, pet cat or dog in first 6 mo for 1 subject, and pet cat or dog between age 6 and 36 mo for 2 subjects. VDAART, Vitamin D Antenatal Asthma Reduction Trial.

HHS Vulnerability Disclosure